Table 1 Clinical features of the population under study
Clinical characteristics | Control group (number = 32) | Obese group (number = 97) | Pvalue | Overall (number = 129) |
|---|---|---|---|---|
Age (years) | 60.9 ± 11.5 | 46.7 ± 13.4 | <0.0001 | 50.2 ± 14.3 |
Weight (Kg) | 71.9 ± 13.6 | 120.7 ± 26.3 | <0.0001 | 108.7 ± 31.8 |
BMI (Kg/m2) | 26 ± 4.5 | 44.6 ± 7.9 | <0.0001 | 40 ± 10.8 |
Associated diseases and treatments | ||||
Diabetes | 5 (15.63%) | 28 (28.86%) | N.S. | 33 (25.58%) |
Dyslipidemia | 10 (31.25%) | 36 (37.11%) | 0.054 | 46 (35.66%) |
Obstructive sleep apnea | 1 (3.1%) | 32 (33%) | <0.001 | 33 (25.6%) |
Contraceptive | 1 (3.1%) | 3 (3.1%) | N.S. | 4 (3.1%) |
Statin | 3 (9.3%) | 17 (17.5%) | N.S. | 20 (15.5%) |
Immunesuppresive | 1 (3.1%) | 5 (5.15%) | N.S. | 6 (4.65%) |
Antidepressant | 2 (6.2%) | 11(11.34%) | N.S. | 13 (10.07%) |
Nifedipine | 0 (0%) | 10 (10.3%) | N.S. | 10 (7.75%) |
Hormone | 1 (3.1%) | 6 (6.18%) | N.S. | 7 (5.42%) |
Paracetamol | 2 (6.2%) | 7 (7.21%) | N.S. | 9 (6.97%) |
Serological assessments | ||||
AST (U/L) | 26.8 ± 12.9 | 24.7 ± 12.9 | N.S. | 25.2 ± 12.9 |
ALT (U/L) | 31.8 ± 20 | 32.7 ± 21.8 | N.S. | 32.4 ± 21.3 |
GGT (U/L) | 53 ± 46.4 | 35.6 ± 29.3 | N.S. | 40.2 ± 35.3 |
ALP (U/L) | 99.9 ± 48.5 | 71.6 ± 22.4 | <0.01 | 79.7 ± 34.3 |
Triglycerides (mg/dL) | 106.9 ± 54.1 | 163.3 ± 154.8 | <0.01 | 148.5 ± 137.8 |
Cholesterol (mg/dL) | 190.6 ± 54.1 | 200.8 ± 42.6 | N.S. | 198.2 ± 45.9 |
Liver triglyceride content - Biochemical assay (mg/g) | 33.3 ± 28.3 | 94.5 ± 57.1 | <0.0001 | 79.3 ± 57.8 |